Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
about
Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleedingKey role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flowPlatelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseTowards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assayBinding of thrombin-activated platelets to a fibrin scaffold through α(IIb)β₃ evokes phosphatidylserine exposure on their cell surfaceThe C-terminal CGHC motif of protein disulfide isomerase supports thrombosis.Clinical use of new antithrombotic therapies for medical management of acute coronary syndromesAbciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factorPharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjectsPharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humansPotent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trialHigh-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton.WASP plays a novel role in regulating platelet responses dependent on alphaIIbbeta3 integrin outside-in signallingProcoagulant profile in patients with immune thrombocytopenia.Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges.Protein 4.1R-deficient mice are viable but have erythroid membrane skeleton abnormalities.Glycoprotein IIb/IIIa and P2Y12 induction by oligochitosan accelerates platelet aggregation.Potential role for rFVIIa in transfusion medicine.A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant propertiesThe long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease.Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.Acute vertebrobasilar occlusion: current treatment strategies.Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets.Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice.Platelet-dependent thrombography gives a distinct pattern of in vitro thrombin generation after surgery with cardio-pulmonary bypass: potential implications.beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failureClinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.Characterizing blood microparticles: technical aspects and challenges.A bumpy and winding but right path to domestic drug-eluting coronary stents.Structural and mechanistic insight into how antibodies inhibit serine proteases.Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins.Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeuticsPast, present, and future of anti-platelet therapy.Monocytes regulate systemic coagulation and inflammation in abdominal sepsis.Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1.Key role of integrin α(IIb)β (3) signaling to Syk kinase in tissue factor-induced thrombin generation.Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.Platelets inhibit the lysis of pulmonary microemboli.
P2860
Q24299751-432400C2-FE3D-4017-AF34-F46C97C22FD9Q24305071-F0F4CAE6-D39C-4DBC-A481-DB15F15C27FCQ24793321-5B6123C4-CBC1-4913-AB7A-F5343C692416Q24812269-6BA6FE06-1ED8-45A6-B81F-B5B7AF5EB79CQ27316701-BC8C7D51-8EE0-4120-B737-AE8CAF1E7756Q27332350-07320F33-D1FF-4A72-AB5A-41C252EE6CA0Q28177271-5934A9B4-1099-4F7B-B658-FBAAA52A1F4FQ28183647-6053F2D0-3FE1-43A6-9054-32E6F44EDCD5Q28189075-CD850D19-58EA-4563-B791-7D525DB6A001Q28199325-558775E8-3683-4724-A737-4138DB3F659CQ28214135-02D2FBE6-2B70-490E-951C-B1F8EB4C5150Q33338284-963A954D-B6C3-4FF5-8574-26BEF1249068Q33372685-FE3FD2AB-CEDE-4E74-8033-5C044FE09FF1Q33386825-3CD5D81F-AE64-455A-B621-15F65F3430D3Q33436189-48569A4E-17F7-4595-B609-BAAD8BDA9443Q33615785-ED5BC2FB-C9D7-4E42-BFFA-09CE078533B8Q33835575-23E37619-DE9F-4EAF-B8BC-04ECD682AB5FQ34176926-75F074BD-41A2-423D-8869-FFA214E779D0Q34564930-E4D03E1B-0FFE-4BF7-8855-202C5776B648Q35849995-7D79DCCD-1AFA-4034-B3AB-418BD07A78DBQ35936923-50B49935-5B90-4D29-93FD-0C6F80B4F5E8Q35937178-5E472689-AFED-44D8-8902-CD6EA68435E0Q36273731-9C9ED9AE-3C6D-413B-9FB4-A0E6503EE5A3Q36288115-3B8BC47C-2A83-4648-97E1-9146F4F41992Q36376147-5B0E5F76-5139-4EAE-AFE0-9DE9C8B6ACF8Q36467593-D7CB639B-B579-4854-B38D-EBCC6032F387Q36507782-13F211ED-AA3D-4319-AB64-8FC6FBE7CCF7Q36536184-8A04674F-83CD-4A48-9BAE-6D99DBBEF5D2Q37004064-88E52375-C3FC-4E83-8DB2-D467B9DB2D4DQ37316783-193DCAB3-744D-48DD-A45C-DB704EA321ECQ37779571-D26832C7-9249-43EC-92CE-72DA628ADFDEQ39550459-2BDD30A1-9210-46E5-B6F0-592A5E0F2AB2Q39781545-B11A95B0-0F49-4F02-A046-F7EB2D37A7C6Q40109317-BA8ABFF0-1E78-445F-9905-7A50B88D9B63Q41602019-4E640A1C-9883-420A-AF05-C6167813883BQ41884542-583DC33D-C19B-413A-87AB-1499D909C0FFQ42326086-A98362F4-BB1D-42FB-A424-A6A8DDDF9947Q43562848-4D66C989-1930-414B-9E9D-6D5F5A443470Q43591838-75D14C2A-8246-4CC8-A4AE-8A5ADF4D3A9CQ43882361-ADEB0E35-A87F-4A50-9E1B-A1F98CB81CEF
P2860
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of platelet-mediate ...... sis and "clinical restenosis".
@en
Inhibition of platelet-mediate ...... sis and "clinical restenosis".
@nl
type
label
Inhibition of platelet-mediate ...... sis and "clinical restenosis".
@en
Inhibition of platelet-mediate ...... sis and "clinical restenosis".
@nl
prefLabel
Inhibition of platelet-mediate ...... sis and "clinical restenosis".
@en
Inhibition of platelet-mediate ...... sis and "clinical restenosis".
@nl
P2093
P2860
P356
P1476
Inhibition of platelet-mediate ...... sis and "clinical restenosis".
@en
P2093
P2860
P304
P356
10.1172/JCI118859
P407
P577
1996-08-01T00:00:00Z